复方中药干预代谢相关脂肪性肝病的研究进展

孙屿昕; 童光东

doi:10.3969/j.issn.2096-3351.2025.01.003

西南医科大学学报 ›› 2025, Vol. 48 ›› Issue (01) : 11 -16. DOI: 10.3969/j.issn.2096-3351.2025.01.003

专家论坛

复方中药干预代谢相关脂肪性肝病的研究进展

孙屿昕 ¹ ,
童光东 [中] ¹^,²^,*

作者信息 +

Research Progress on the Intervention of Metabolic Associated Fatty Liver Disease with Compound Traditional Chinese Medicine

Yuxin SUN ¹ ,
Guangdong TONG ¹^,²^,*

Author information +

文章历史 +

PDF (875K)

摘要

代谢相关脂肪性肝病（metabolic associated fatty liver disease， MAFLD）已成为全球性卫生健康问题，至今很少有治疗药物被批准上市，其复杂的发病机制导致药物研发面临着极大的挑战。本文简述了国内外MAFLD药物研发现况，以及复方中药干预MAFLD的临床研究与新药开发，通过基础研究发现，复方中药可以通过综合干预多靶点、多通路调节，改善脂质代谢、减轻炎症及纤维化、调节肠道微生物群，提示复方中药可能是未来MAFLD治疗潜在新药开发领域之一。本文就复方中药干预代谢相关脂肪性肝病作一述评，以期为临床提供参考。

Abstract

Metabolic associated fatty liver disease（MAFLD） has become a global health problem， so far， few drugs have been approved for marketing， and its complex pathogenesis has led to great challenges in drug development. In this paper， the current status of MAFLD drug research and development at home and abroad， as well as the clinical research and new drug development of compound Chinese medicine in the treatment of MAFLD were summarized. Through the basic research of compound Chinese medicine， it was found that compound Chinese medicine could improve lipid metabolism， reduce inflammation and fibrosis， and regulate intestinal microflora through comprehensive intervention of multi-target and multi-pathway regulation. It is suggested that compound Chinese medicine may be one of the potential new drug development fields for MAFLD treatment in the future. This article reviewed the intervention of metabolic-related fatty liver disease with compound traditional Chinese medicine, aiming to provide a reference for clinical practice.